

FANGDA PARTNERS
方達律師事務所

Life Sciences and Healthcare





The Firm

Founded in 1993 and one of the most prestigious law firms in the region, Fangda Partners has more than 900 lawyers. We serve a wide variety of major clients – including large MNCs, global financial institutions, leading Chinese enterprises and fast-growing Hi-tech companies – on an extensive range of commercial matters through our network offices in Beijing, Guangzhou, Hong Kong, Nanjing, Shanghai, Shenzhen and Singapore, offering PRC law and Hong Kong law.

We are the firm of choice for clients' most challenging transactions and legal issues in many practice areas. Since we were founded, we have advised on some of the largest and most complex corporate and finance transactions in China, the region and globally. We have also assisted our clients with many renowned and complex cases and arbitrations, and compliance and government investigations in the region.

Our service to clients is premised on the dual foundations of strong local law capabilities and a global business outlook. Our lawyers are qualified in many jurisdictions, including the Chinese Mainland, Hong Kong SAR, England and Wales, the United States, Singapore and Australia.

Our understanding of the laws and processes in major jurisdictions around the world enables us to advise our clients effectively on the largest and most complicated cross-border matters in China and elsewhere. Our strengths have been widely recognized by our clients and peers. Chambers has commented on our cross-border capabilities in the following terms – "outstanding quality of its lawyers", "high level of service that is comparable to international firms", and "strong global outlook".



Fangda is a well-known full-service firm advising both international and local clients on the healthcare industry. Its clients include high-profile pharmaceutical and biotech companies, private equity firms and blue-chip medical device companies. Leveraging the firm's wider expertise, the team is well experienced in handling IP, M&A, capital markets and regulatory compliance as well as government investigation and enforcement matters.

—— **Chambers Greater China 2026**



China Business Law Awards: Golden League Awards
China Business Law Journal, 2026



International and Cross-Border Capabilities Law Firm of the Year (PRC Firm)
Chambers Greater China Region Awards, 2026



Jurisdictional Law Firm of the Year: China firm of the year
IFLR1000 Asia-Pacific Awards, 2025



China Firm of the Year
China Law & Practice Awards, 2025



Deal of the year - Corporate & M&A: PRC Firms
Legal 500 China Awards, 2025



Private Equity & Venture Capital Firm of the Year – China
China Law & Practice Awards, 2025



Jurisdictional Firm of the Year: China – Restructuring firm of the year
IFLR Asia-Pacific Awards, 2025



GAR100 Law Firm
Global Arbitration Review (GAR) 100, 2025



Intellectual Property Firm of the Year - China
China Law & Practice Awards, 2025



Banking and Finance: PRC Firms
Legal 500 China Awards, 2025

Our Life Sciences and Healthcare Practice

Focused service team

We are one of the few law firms in China that has a dedicated team in the pharmaceutical, biotechnology and healthcare sector. We provide the full range of business legal services to pharma, biotechnology and healthcare businesses. Some of our team members have worked for leading pharmaceutical and medical device companies and regulatory authorities. We combine legal expertise with keen commercial understanding to enable our clients to achieve their business objectives with the minimum of fuss.

Extensive range of experience

Our life sciences and healthcare practice provides a wide range of services. Our past experience in the industry covers mergers and acquisitions, product-driven transactions, foreign direct investment, investments by private equity funds and venture capital, domestic and overseas capital markets, compliance, in-license and out-license, commercial bribery, data protection, vertical and horizontal monopoly arrangements, IP enforcement and regulatory advice. We have specialist expertise in advising on complicated commercial transactions with a high degree of regulatory impact (such as those involving drugs and medical devices), where extensive industry savvy and a combination of expertise in different disciplines is required, in addition to routine deal execution skills.



The respected life sciences and healthcare team at Fangda Partners has a strong track record in a variety of transactions and contentious issues.

— **Chambers Greater China 2026**

"In addition to in-depth understanding of the biopharmaceutical industry and keen insight into the current status of the industry, they also provide a variety of services, including compliance, antitrust, litigation, real estate, etc., which is relatively comprehensive."

— **Client comments, Legal 500 2025**

Diversified clientele

Our clients range from large and medium-sized multinational pharmaceutical companies, research-based pharmaceutical companies, medical device companies, distributors, contract sales organizations, contract research organizations, and industry associations to private equity funds and venture capital businesses. We advise companies headquartered in the U.S., Europe, China and across Asia.

Our lawyers have deep knowledge of the sector, enabling us to advise on the full range of legal issues that arise from our clients' businesses. This includes in-depth understanding of research and development, clinical trials, manufacturing/contract manufacturing services, and distribution/retail/logistics of pharmaceutical products and medical devices, as well as the establishment, operation and management of hospitals, personal clinics and innovative healthcare service platforms.



Healthcare and Life Sciences (PRC Firms): Tier 1
Legal 500, Asia Pacific-China(Mainland), 2019-2026



Healthcare (PRC Firms): Band 2
Chambers, Greater China Region Guide, 2022-2026

One legal solution across multiple practices

As the life sciences and healthcare sector faces increased complexity and challenges, all businesses – from start-ups (even in the very early stage of inception of business) to multinational companies - require in-depth legal assistance across the full range of practices. As a first-class, fully integrated, full services law firm, we are able to offer just such a comprehensive service, and are set up in such a way to offer clients a seamless service across offices and practice areas. We provide integrated teams drawn from different legal disciplines to cover every angle of a deal. We recognize the importance of identifying early the key legal issues and planning a strategy to ensure the most effective management of any transaction on which we are retained. One team, one solution is our well-developed method of working.



Pharmaceuticals and life sciences: Highly recommended
Asialaw Profiles, China, 2022-2025



Healthcare & Life Science Firm of the Year – China
China Law & Practice Awards, 2021-2022



Healthcare (PRC Firms): Band 2
Chambers, Asia-Pacific, 2019-2021





Mergers and Acquisitions & Direct Investment

Fangda is the undisputed leader among law firms advising on mergers and acquisitions in China. Our lawyers have paved the way in developing the legal practice in this field. We have helped many clients successfully execute their critical mergers and acquisitions. We are also the market leader in foreign direct investment and domestic and overseas capital markets transactions. Among other transactions, we have advised on Sino-foreign joint ventures, business restructuring and takeovers of listed companies.

Our experience spans many sectors, including pharmaceutical, biotech, medical devices, contract research organization, physical inspection and disease screening, wellness management and medical services.

Market-leading IP, life sciences collaborations and licensing, data privacy, regulatory, credit finance, antitrust & competition, employment and tax practices to support all types of transactions.



中国生物制药
SINO BIOPHARMACEUTICAL



HYGIEIA
Pharmaceuticals

Sino Biopharmaceutical's Acquisition of Hygieia

Represented Sino Biopharmaceutical in its acquisition of 100% equity of Hygieia Pharmaceuticals.



AnHeart
Therapeutics
葆元医药



Nuvation Bio

AnHeart Therapeutics' All-Stock Acquisition by Nuvation Bio

Represented AnHeart Therapeutics in connection with its acquisition by Nuvation Bio, a U.S.-listed biopharmaceutical company, in an all-stock transaction.



Kyowa KIRIN
协和麒麟(中国)制药有限公司



维健医药
WINHEALTH PHARMA

Kyowa Kirin's Asia-Pacific Business Restructuring

Represented Kyowa Kirin on its Asia-Pacific restructuring, transferring Kyowa Kirin China's entire equity to WinHealth Pharma and granting WinHealth China commercialization and production rights for five originator brands and two global products.



OPM
奥浦迈



瀚立生物
PharmaLegacy

OPM Biosciences' Acquisition of 100% Equity Interest in PharmaLegacy Laboratories

Represented STAR Market-listed OPM Biosciences (688293.SH) in its landmark "dual first-of-its-kind" restructuring to acquire 100% of PharmaLegacy Laboratories via share issuance and cash payment, alongside supporting fund-raising.



AstraZeneca's Investments in Manufacturing Facilities in China
Represented AstraZeneca in connection with its investments of more than RMB10 billion in new manufacturing facilities in Qingdao, Taizhou and Wuxi.



AstraZeneca's Cell Therapy Manufacturing Facility in Shanghai Lingang
Represented AstraZeneca in connection with the construction of a commercial cell therapy manufacturing and supply facility in the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone.



Combination of Mylan with Upjohn
Represented Mylan in the combination of Mylan with Upjohn, Pfizer's off-patent branded and generic established medicine business, creating a new global pharmaceutical company.



Eddingpharm's Acquisition of Eli Lilly Products
Represented Eddingpharm on its acquisition of two antibiotic products sold by Eli Lilly in China, Ceclor and Vanocin, as well as its Ceclor manufacturing facility in Suzhou with a total transaction value of US\$375 million.



WuXi AppTec's Joint Venture with Mayo Clinic
Represented WuXi AppTec in its establishment of a joint venture with Mayo Clinic. Mayo Clinic is a nonprofit worldwide leader in medical care, research and education.



China Everbright Limited's Acquisition of LifeTech
Represented China Everbright on its acquisition of 22.4% of the shares in LifeTech, a leading cardiovascular device manufacture in China listed on the HKEX for US\$126 million.



Bayer AG's Acquisition of Dihon Pharmaceutical
Advised Bayer on its acquisition of Dihon Pharmaceutical Group for about RMB3.6 billion. This deal was recognized as Deal of the Year 2015 by China Business Law Journal.



Privatization of WuXi AppTec
Provided legal services for China's biggest CRO, WuXi AppTec, in its privatization from NASDAQ.



Bayer and Merck's Domestic Restructuring of OTC Business
Advised Bayer HealthCare China in its integration with the onshore part of Merck OTC Business, following Bayer's global acquisition of Merck OTC department.



Privatization of CBPO
Represented Centurium Capital and other investors in the proposed privatization of China Biologic Products Holdings Inc., a leading fully integrated plasma-based biopharmaceutical company in China, from NASDAQ.



MicroPort's acquisition of Argus
Represented MicroPort in its controlling stake acquisition of Argus, a leading medical imaging products manufacturer.



CBC Group & Hasten's acquisition of exclusive right from Takeda
Assisted CBC Group and Hasten in the closing of acquisition of the Chinese Mainland-exclusive rights of five cardiovascular and metabolism drugs from Takeda.

Licensing and Strategic Partnering

Our licensing team is well-versed in the business, regulatory and commercial issues inherent in transactions and strategies, and committed to collaborating thoughtfully with each client to apply their knowledge and skill set using a pragmatic, results-oriented approach.

Fangda's leadership in representation of life sciences companies has allowed us to build a unique and extensive understanding of biotech's and pharma's perspective, needs and deal drivers for corporate partnering, licensing and commercial transactions.

"Whether it is routine consultations or urgent matters, the team can respond immediately, providing clear and targeted legal advice to ensure the continuity and compliance of the client's operations."

—Client comments,
Chambers Greater China 2026



TJ Biopharma's License of Felzartamab to Biogen

Represented TJ Biopharma in entering into a collaboration agreement with Biogen for the Exclusive Rights of Felzartamab in the Greater China Region.



LaNova Medicines' Exclusive Global License of LM-299 to MSD

Represented LaNova Medicines in granting MSD an exclusive global license to LM-299, a PD-1/VEGF bispecific antibody.



Zelgen's Overseas License of DLL3 trispecific antibody (ZG006) to AbbVie

Represented Zelgen in entering into a strategic collaboration and option-to-license agreement with AbbVie for Zelgen's DLL3 trispecific antibody (ZG006) worldwide (excluding China mainland, Hong Kong and Macau).



OTR Therapeutics' Multi-Program R&D Collaboration and License Agreement with Zealand Pharma

Represented OTR Therapeutics in entering into an R&D collaboration and license agreement with Zealand Pharma covering multiple metabolic disease targets.



Qyuns' exclusive global License of QX031N to Roche

Represented Qyuns Therapeutics in granting Roche an exclusive global license to the long-acting autoimmune bispecific antibody QX031N.



Genrix Bio's Exclusive Ex-Greater China License of Velinotamig to Cullinan Therapeutics

Represented Genrix Bio in granting Cullinan Therapeutics an exclusive license outside Greater China to Velinotamig, a BCMA×CD3 bispecific antibody.





Qyuns Therapeutics' Exclusive Ex-Greater China License of QX027N to Windward Bio



Represented Qyuns Therapeutics in entering into a license and collaboration agreement with Windward Bio for the development and commercialization of QX027N outside Greater China.



AstraZeneca's Sub-license of Adenovirus Vector-Based COVID-19 Vaccine to BioKangtai



Advised AstraZeneca in granting BioKangtai the exclusive license in China in relation to AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University.



Qyuns Therapeutics' Exclusive Global License of QX030N and Equity Collaboration with Caldera Therapeutics



Represented Qyuns Therapeutics in granting Caldera Therapeutics an exclusive global license to QX030N and acquiring a minority equity interest in the NewCo.



AnHeart's License of Next Generation TKI Therapy to Innovent

Advised AnHeart Therapeutics in granting an exclusive commercialization right in the PRC market to Innovent in relation to AnHeart's lead drug candidate taletrectinib, a next-generation tyrosine kinase in-hibitor (TKI), designed to effectively target ROS1 and NTRK.



Huaota Biopharmaceutical's Global R&D Collaboration and License Agreement with Almirall



Represented Huaota Biopharmaceutical in entering into a global R&D collaboration and license agreement with Almirall for an innovative monoclonal antibody.



AstraZeneca's Strategic Collaboration with Luye Medicine



Advised AstraZeneca in connection with its acquisition from Luye Medicine of the exclusive rights to promote Xuezhikang Capsules in Mainland China.



Junshi Biosciences' Collaboration with Fosun Wanbang for Roconkibart (IL-17A)



Advised Junshi Biosciences on its R&D and commercialization collaboration with Fosun Wanbang for Roconkibart (IL-17A) in the Greater China region (including the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).



AstraZeneca's License of Plendil



Advised AstraZeneca in connection with its granting to China Medical System of exclusive commercialization rights of Plendil in China, for a US\$310 million upfront license fee.



Duality Biotherapeutics' License of HER2 ADC to 3SBio Inc.



Advised Duality Biotherapeutics on its collaboration with 3SBio Inc. for commercialization of HER2 ADC in Greater China region (including the Chinese mainland, Hong Kong Special Administrative Region, and Macao Special Administrative Region).



CStone's License of CS1002 to Hengrui



Advised CStone Pharmaceuticals in granting the exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.



AstraZeneca's Licensing and Strategic Collaboration with Syneron Bio



Advised AstraZeneca on its licensing and strategic collaboration with Syneron Bio relating to Syneron Bio's macrocyclic peptide drug discovery platform, as well as AstraZeneca's equity investment in Syneron Bio.



OnCusp Therapeutics' license-in from Multitude

Represented OnCusp Therapeutics in the license-in of exclusive rights to develop, register and commercialize an anti-CDH-6 antibody conjugated drug, from Multitude, in the worldwide (except Greater China).

Capital Markets

Fangda is widely recognized as being a leading capital markets practice in China and Hong Kong. We have longstanding experience advising clients on A-share listings on the SSE and SZSE, as well as on IPOs on the HKEX and other overseas exchanges. We represent issuers, underwriters and sponsors in IPOs both as PRC and Hong Kong counsel. We have particular expertise in the healthcare sector.

As **PRC counsel**, we advised on the largest A-share IPO projects in 2018 and pioneered the privatization of companies for A-share IPOs. We have also advised on the privatization of more than 20 U.S.-listed companies. We are fully familiar with the employee stock ownership plans (ESOPs) of U.S.-listed companies and other compliance practices.

As **Hong Kong counsel**, our team also has extensive experience in HKEX IPO projects. We have been singled out by the HKEX for the quality of the prospectuses that we have drafted. We have developed a close business partnerships with the institutional decision makers, bankers and investors in Hong Kong, which enables us to deliver real insight into capital markets transactions of size and complexity. We have advised on many Chapter 18A listings of biotech companies on the Hong Kong Stock Exchange.

Fangda Partners is a solid corporate practice with extensive experience in overseas equity and debt offerings, including IPOs and H-share convertible issuance. It is known for advising on listings in the USA, Singapore and Hong Kong. The team is equipped to handle corporate bonds, perpetual bonds and panda bonds issuances.

--Chambers Greater China 2026



HKEX Listing of XtalPi

Advised XtalPi in connection with its listing on the Main Board of HKEX, raising approximately HKD 896 million. XtalPi is an innovative platform focusing on research and development and combining the technologies involving quantum physics, AI, cloud computing and large-scale robotics. This is the first listing completed in accordance with Chapter 18C of the Hong Kong Listing Rules in connection with specialist technology companies.



Separate Listing of WuXi XDC on HKEX

Advised WuXi XDC in connection with its spin-off from WuXi Biologics for a separate listing on the Main Board of HKEX and global offering, raising approximately HKD3,676 million. WuXi XDC is a leading CRDMO focusing on the global antibody-drug conjugate (ADC) and broader bioconjugate market dedicated to providing integrated and comprehensive services.



STAR Market Listing of InnoCare

Advised InnoCare Pharma Limited on its successful listing on the Shanghai Stock Exchange's STAR Market, raising a total of about RMB2.9 billion. InnoCare is an innovative biopharmaceutical enterprise powered by its groundbreaking independent research and development capabilities, focusing on developing drugs for the treatment of cancer and autoimmune diseases.



HKEX Listing of Xuanzhu Biopharm

Assisted Xuanzhu Biopharm in listing on the Main Board of the Hong Kong Stock Exchange, raising approximately HKD 780 million. Xuanzhu Biopharm is an innovative drug research and development company spun off from Sihuan Pharmaceutical Holdings Group Ltd. Its core business focuses on the research, development, and industrialization of innovative drugs in the fields of digestive diseases, oncology, and non-alcoholic steatohepatitis (NASH).



HKEX Listing of New Horizon Health

Advised New Horizon Health, a market leader in cancer screening in China, on its Chapter 18A HKEX listing, raising approximately HK\$2 billion. New Horizon's shares IPO were significantly over-subscribed and the share price increased by 185% when trading commenced on February 18, 2021.



NASDAQ Listing of Genetron Health

As PRC legal counsel to Credit Suisse Securities (USA) LLC and China International Capital Corporation Hong Kong Securities Limited as underwriters on the IPO and listing of Genetron Holdings Limited (Genetron) on the Nasdaq Global Select Market in the US on June 19, 2020.



HKEX Listing of CStone Pharmaceuticals

Advised CStone Pharmaceuticals, a leading innovative biopharmaceutical company in China, on its HKEX listing, raising approximately HK\$2.4 billion.



Listing of WuXi AppTec on SSE and HKEX Main Boards

As the PRC and Hong Kong counsel, advised WuXi AppTec, the largest CRO in China, on its delisting from NASDAQ, its listing on SSE Main Board in May 2018 (raising approximately RMB2.2 billion) and its initial public offering on HKEX in December 2018 (raising approximately US\$1 billion).



HKEX Listing of WuXi Biologics

Represented WuXi Biologics, China's largest service provider of biological products, on its successful IPO on the HKEX, raising approximately HK\$3.8 billion.



Listing of BeiGene on STAR Market, HKEX and NASDAQ

Represented BeiGene in connection with its initial public offering on the STAR Market (raising approx. RMB22.16 billion), the HKEX Main Board (raising approx. USD903 million) and on the NASDAQ (raising approx. USD169.4 million).



Listing of Mindray on SZSE ChiNext Board

Represented Mindray, a global leading developer and provider of medical devices and solutions, on its listing on the ChiNext Board of SZSE, raising RMB5.9 billion. To date, this was the largest IPO on the ChiNext Board.



SSE Listing of Konruns

Advised Konruns Pharmaceutical on its IPO and listing on the SSE Main Board, raising approximating RMB974 million.



Chapter 18A Listing of Hua Medicine

Represented the underwriters on the IPO of Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes and one of the first to list under Chapter 18A.



Hong Kong IPO of JW Therapeutics

Acted as Hong Kong counsel to JW (Cayman) Therapeutics Co. Ltd. (Stock code: 2126) on the listing of JW Therapeutics' ordinary shares on the Main Board of the Stock Exchange of Hong Kong and the concurrent global offering. The listing and global offering raised approximately HK\$2.3 billion (prior to exercise of the underwriters' over-allotment option).



Chapter 18A Listing of Innovovent on HKEX

Represented Temasek, the Singapore investment company, on the Chapter 18A listing of Innovovent on the HKEX Main Board.



Hong Kong IPO of Frontage

Represented Frontage Holdings Corporation, a subsidiary controlled by Hangzhou Tigermed Consulting Co., on its submission of listing application documents to the HKEX.

Hong Kong Listing of Hospitals and Healthcare Companies

Advised Jinxin Fertility, Harmonicare Medical, Wenzhou Kangning Hospital, Jacobson Pharma, Sihuan Pharm, Pioneer Pharma, Besunyen and Sinco Pharmaceuticals on their HKEX IPOs.

Private Equity and Venture Capital

We have a highly regarded private equity and venture capital practice and are one of the few law firms that is able to provide the full scope of legal advice in the private equity practice area in China, as well as having one of the longest track records of advising on transactions. We have the capability to provide “one-stop shop” services to private equity firms, financial investor clients and their portfolio companies on every aspect of their business endeavors – from fund formation and portfolio investments to investment disposals and exits.

Within the life sciences and healthcare sector, we have advised on the largest, most notable and most complex private equity transactions in China. Our knowledge and experience are geared to ensuring that clients can successfully pursue their funds-related business. Our clients include TPG, MBK Partners, Goldman Sachs, CITIC Capital, Yunfeng Capital, Hillhouse Capital, and Olympus Capital.

Fangda Partners boasts a market-leading team with a deep bench of specialists who are frequently instructed by high-profile domestic and international private equity firms.

— **Chambers Greater China 2026**



Excalipoint Therapeutics' Financing

Represented Excalipoint Therapeutics in establishing a new offshore structure and completing its Series A preferred equity financing, co-led by HongShan Capital, YuanBio Capital and Apricot Capital, and in obtaining an exclusive global license from Lepu Biopharma for the development and commercialization of two T-cell engager programs.



Qiming Venture Partners and BioTrack Capital's Investment in Bioheng Therapeutics

Represented Qiming Venture Partners and BioTrack Capital as co-lead investors in the Series C financing of Bioheng Therapeutics, a clinical-stage biotechnology company focused on CAR-T therapies.



CDH's Investment in Syneron Bio

Represented CDH in its Series B investment of Syneron Bio, with a total financing of approximately USD 150 million.



AliHealth's Investment in Mandi

Represented Alibaba Health (Hong Kong) Technology Company Limited as a Series A investor in the final round of financing prior to Mandi Inc.'s application for a Main Board listing on the Hong Kong Stock Exchange.



Quan Capital's Investment in Zenas

Represented Quan Capital as an existing investor in its equity investment in the Zenas Series C financing, with a total transaction value of USD 200 million. Zenas is a global biopharmaceutical company committed to becoming leader in the development and commercialization of inflammation and immunology-directed therapies.



CPE's Investment in Sangon Biotech

Advised CPE on its investment in Sangon Biotech, a leading China-based life sciences company offering a wide range of life sciences products and services. CPE and GL Capital were the lead investors and the total amount raised by Sangon Biotech and its existing shareholders in this pre-IPO round of financing was approximately RMB2 billion.



C-MER's Investment in Chigenovo

Represented C-MER Medical Holdings Limited in its proposed approximately RMB 110 million investment in Beijing Chigenovo Co., Ltd. (a leading Chinese ophthalmic gene therapy company incubated by Peking University Third Hospital) in its Series B financing, for approximately 10.23% equity, becoming second largest shareholder.



YolTech Therapeutics' Financing

Represented YolTech Therapeutics in its Series C financing of nearly RMB 500 million. YolTech Therapeutics is advancing in vivo gene-editing medicines for genetic diseases and cardiovascular diseases.



Embios' Financing

Represented Embios in its Pre-A and Series A financing. Embios is an innovative drug development company.



Pyrotech Therapeutics' Financing

Represented Pyrotech (Beijing) Biotechnology Co., Ltd. in its Series A financing, involving an aggregate financing amount of RMB 700 million. Pyrotech Therapeutics is an enterprise focusing on developing revolutionary and innovative drugs for the treatment of inflammation and tumors.



Hasten Biopharma's Financing

Represented Hasten Biopharma in its Series A financing led by CBC Group, involving a transaction price of USD315,000,000.



Eddingpharm's Series E financing

Represented Eddingpharm in its US\$140 million Series E financing led by OrbiMed and Sequoia.



DCP's investment in Tonghua Dongbao

Represented DCP in its acquisition of a 9% stake in A-share listed Tonghua Dongbao Pharmaceutical Co., Ltd. from Dongbao Industrial Group Limited, for approximately US\$283 million.



MicroPort Medical Robot's Financing

Represented MicroPort Medical Robot in connection with its RMB3 billion financing from Hillhouse Capital and CPE, among others.



Ant's Investment in Meixin

Represented Ant Group and other investors in their RMB1 billion investment in Meixin Health, the leading innovative healthcare service group.



Everbright's investment in Shenzhen Lifetech

Representing Everbright Holdings in its investment in Shenzhen Lifetech (01302.HK), the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases.



Boyu's Acquisition of Gloria Pharmaceuticals

Acted for Boyu Capital, 6 Dimensions Capital and other investors on their investment in Gloria Biotechnology, a wholly-owned subsidiary of Harbin Gloria Pharmaceuticals Co. (an A-share listed company), and on their acquisition of a 51% equity stake in Gloria Biotechnology.



PAG's Investment in Alphamab

Represented PAG and CVC on their subscription of Series A preferred shares of Alphamab, a company dedicated to the development and commercialization of biopharmaceuticals for cancer treatment. PAG and CVC invested US\$34 million and US\$25 million, respectively.



云锋基金



Yunfeng Capital's Investment in Livzon Biologics

Advised Yunfeng Capital on its US\$148 million equity investment in Livzon Biologics, a subsidiary controlled by Livzon Pharmaceutical Group Inc., an A-share listed company.



TPG's Acquisition of United Family Hospital's Parent Company

Represented TPG in its US\$460 million acquisition, together with Fosun Pharm, of Chindex International, Inc., the parent company of United Family Health.



TPG Capital's Acquisition of Majority Stake in OPC

Represented TPG Capital in its acquisition of a majority stake in OPC, a leading clinical trial group across Asia.

Regulatory Advisory

We advise a wide range of healthcare companies on general operational and regulatory issues, including advising on compliance and dealing with regulatory authorities such as the National Medical Products Administration. Among other issues on which we have expertise, we can advise clients on:

Market entry

- Legal vetting of innovative business models under existing regulatory environment
- Market approval system of drugs or medical devices, and related arrangements
- Restrictions on foreign investment in China and appropriate structuring for foreign capital

R&D/Clinical trials

- Contracts and associated legal documents relating to R&D and clinical trials
- Patient recruitment, engagement with investigator, disputes arising from death or injury, and other legal issues associated with participating in trials
- Compliance requirements (data protection, HGR administration, anti-bribery) relating to clinical trials
- Issues associated with real world evidence (RWE) trials

Product Promotion Activities

- Compliance issues in product promotion, such as advertising of medicine products and marketing
- Conduct of medical representatives
- Distribution models and cooperation with distributors, pharmacies and contract sales organizations
- Bidding and tendering requirements, group purchases and procurement

Patient-centric Transformations

- Regulatory issues in interaction with patients, patient advocacy groups and NGOs
- Program design and regulatory compliance review of various types of patient support programs
- Implementation of PAPs, PSPs and other patient assistance programs.
- Cooperation with online hospital and other types of digital transformation programs
- Innovative payment plan

"Their proficiency is evident in their strategic approach to cross-border legal challenges and their adept handling of regulatory and compliance issues that directly impact our business."

—— **Client comments,**
Chambers Greater China 2025

Compliance and Investigation

Fangda is renowned for the full spectrum of expertise offered by our team in compliance and investigation matters. Our team comprises former law enforcement officials, judges, and in-house counsels, as well as compliance lawyers who are from both international and local law firms and qualified to practice in the PRC, the U.S., the U.K. and Hong Kong. We have particular experience of advising on Foreign Corrupt Practices Act (FCPA) issues and anti-commercial bribery in China.

Compliance


We advise clients on:

- compliance policies and programs, as well as providing training (such as issues involving anti-corruption, data privacy and network security)
- due diligence (such as due diligence in connection with third parties and on target companies)
- internal investigations (including internal investigations triggered by government investigations, whistleblowing reports or internal audits)
- how to respond to government investigations (including investigations by authorities such as the Administration for Industry and Commerce (AIC))
- criminal proceedings (such as criminal investigations or litigation against the company)
- compliance-related dispute resolution (such as administrative investigations and litigation, labor disputes or non-compliance by employees)



Government investigations

We represented a leading life science company in various contentious matters, including the dissolution of a joint venture, termination of distribution agreements on anti-corruption grounds, and recovering educational grants.




Internal investigations

We have represented several leading life science companies in investigations of potential violations of the FCPA, Chinese commercial bribery laws, accounting fraud and employment issues and other alleged breaches of laws and compliance policies.



Compliance programs and advisory

We have advised many multinational pharmaceutical and medical equipment companies on regulatory reviews relating to administrative investigations of unfair competition and commercial bribery by the SMAR.



Data privacy and network security

We have advised many domestic and foreign companies on legal issues associated with data privacy protection and network security, including on state secrets. We have developed widely recognized protocols that assist clients to navigate a highly complex area. We are at the forefront of research and development of legal policies in this field, engaging with the relevant governmental and regulatory authorities, including SIO, MIIT, MPS, MOF, CSRC, MSS and SAAC.

Intellectual Property

Fangda provides a full range of intellectual property services. We are renowned for our superior knowledge of IP law and assisting our clients to identify, protect, and enhance the value of their intellectual property portfolios through effective strategies in China and beyond. We have extensive experience in IP management and regulatory matters, negotiating cross-border IP transactions, and handling complex IP arbitrations and litigations. We are the preferred choice of intellectual property counsel for many leading healthcare companies, including Novartis, Astellas Pharma, Watson Pharmaceuticals, and others.



Represented **Astellas Pharma** in a number of civil and administrative actions against infringing competitors.



Represented **Watson Pharmaceuticals** in connection with its processing technology-related patent dispute with Eli Lilly, resulting in a final judgment in Watson Pharmaceutical's favor rendered by the Supreme People's Court of China.

Represented **APBI Holding** in administrative litigation against Patent Reexamination Board of SIPO for the validity of its drug patent.



Represented **Aonuo Pharmaceuticals** in a retrial before the Supreme Court in an invention patent infringement case brought by Hubei Wushi Pharmaceuticals.



Represented **Novartis International** in patent disputes against generic companies.



Represented **Pacific Biosciences** in a patent infringement lawsuit involving 3rd generation DNA sequencing technology.



Represented **Pfizer** in a patent review matter concerning anti-tumor compounds before the Beijing Intellectual Property Court

Antitrust and Competition

Fangda is one of the few Chinese law firms with a dedicated antitrust team, and we have one of the largest and most experienced competition teams in China. Our lawyers have deep and unique insight into the PRC and Hong Kong antitrust laws and regulations. Clients come to us for trusted advice on complex and risky antitrust matters. They benefit from our deep understanding of the Chinese regulatory environment and from our engagement with China's competition authorities.

Our team has a market-leading track record of successfully assisting clients on some of the most high-profile merger filings and antitrust investigations in China.

- On merger controls, we advised on 12 of the 22 remedy cases cleared by SAMR (MOFCOM) from 2016 to 2020.
- On antitrust investigations, we have advised clients on more than 30 cases involving cartels, abuses of market dominance and vertical restraints, many of which have been high-profile representative cases.
- On antitrust litigation, we have defended many multinational companies in subsequent civil damages actions and high-profile cases involving abuse of market dominance.

Merger Control

- **Danaher** on its US\$21 billion acquisition of GE Healthcare Life Sciences' Biopharma Business.
- **Becton, Dickinson and Company** on its US\$24 billion merger with C.R. Bard.
- **Merck** in the PRC merger filing in connection with its US\$17 billion acquisition of Sigma-Aldrich, one of the largest global deals in the biotech industry.
- **St. Jude Medical** in the PRC merger filing in connection with its acquisition by Abbott Laboratories for US\$25 billion.
- **Canon** in the PRC merger filing in connection with its RMB38.3 billion acquisition of Toshiba Medical.
- **Novartis** in the PRC merger filing in connection with its establishment of three global joint ventures with GlaxoSmithKline with a total value of US\$20 billion, one of the largest global deals in the pharmaceutical industry.

Antitrust Investigations

- **Medtronic** in an antitrust investigation, the first and so far largest antitrust investigation by the NDRC in the medical device sector.
- **A global leading pharmaceutical company** in an antitrust investigation by Zhejiang AMR.
- **A multinational medical devices company** in an antitrust investigation by Beijing AMR.
- **A multinational medical equipment company** in an antitrust investigation by antitrust enforcement agency
- **A multinational pharmaceutical company** in a NDRC investigation.
- **Toshiba Medical** in connection with the first "gun-jumping" investigation by MOFCOM.

We also regularly advise multinational companies on compliance issues relating to business activities, ranging from providing advice on business contracts (such as innovative sales models after implementation of two-invoice system, territory restrictions or exclusivity requirements) to conducting a full-scale internal review of the corporation on competition law compliance and providing compliance training.

Team Members



Michael Han

Antitrust, Competition Law

+8610 5769 5623
michael.han@fangdalaw.com



Henry He

Licensing, Strategic Partnering,
Financing, M&A and General Corporate

+86 21 2208 1185
henry.he@fangdalaw.com



Colin Law

Hong Kong Capital Markets

+852 3749 1150
colin.law@fangdalaw.com



Diana Li

Mergers and Acquisitions,
Private Equity Investment,
General Corporate

+86 21 2208 1155
diana.li@fangdalaw.com



Chen Lu

Mergers and Acquisitions,
Private Equity Investment,
General Corporate

+86 21 6263 5936
chen.lu@fangdalaw.com



Fang Qi

Intellectual Property


+86 10 5769 5655
fang.qi@fangdalaw.com



Josh Shin

Mergers and Acquisitions,
Private Equity Investment,
Licensing, General Corporate

+86 21 2208 1109
jshin@fangdalaw.com



Bella Wang

Licensing and Collaboration, M&A
and General Corporate

+86 21 2208 5935
bella.wang@fangdalaw.com



Alexandra Yang

Intellectual Property

+86 10 5769 5600
pu.yang@fangdalaw.com



Kate Yin

Compliance and Investigation

+86 10 5769 5617
kate.yin@fangdalaw.com



Derrick Zhao

Compliance and Investigation

+86 21 6263 5829
derrick.zhao@fangdalaw.com



Gil Zhang

Privacy and Data Protection

+86 21 6263 5922
gil.zhang@fangdalaw.com



Beijing

27/F, North Tower
Beijing Kerry Centre
1 Guanghua Road
Chaoyang District
Beijing 100020, China

Tel: +86 10 5769 5600
Fax: +86 10 5769 5788

Guangzhou

66/F, Guangzhou CTF
Finance Centre
6 Zhujiang East Road
Zhujiang New Town
Guangzhou 510623, China

Tel: +86 20 3225 3888
Fax: +86 20 3225 3899

Hong Kong

26/F, One Exchange Square
8 Connaught Place, Central
Hong Kong SAR, China

Tel: +852 3976 8888
Fax: +852 2110 4285

Nanjing

38/F, Asia Pacific Business Building
2 Hanzhong Road
Gulou District
Nanjing 210005, China

Tel: +86 25 8690 9999
Fax: +86 25 8690 9099

Shanghai

24/F, HKRI Centre Two,
HKRI Taikoo Hui
288 Shi Men Yi Road
Shanghai 200041, China

Tel: +86 21 2208 1166
Fax: +86 21 5298 5599

Shenzhen

9/F, Tower One, Kerry Plaza
1 Zhong Xin Si Road
Futian District
Shenzhen 518048, China

Tel: +86 755 8159 3999
Fax: +86 755 8159 3900

Singapore

1 Raffles Place #55-00
One Raffles Place Tower 1
Singapore 048616

Tel: +65 6859 6789
Fax: +65 6358 2345